Financings Roundup: Optimer, Sopherion, Proteon, Pearl
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent alternative financings include direct offerings to institutional investors, a private biotech out-licensing its lead compound to a holding company, and the latest equity/option deal for Novartis’ corporate venture with MPM Capital.